Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To assess the average per-person 96-week HIV treatment costs associated with the three comparators examined in the ACTG 5257 clinical trial, raltegravir (RAL), atazanavir/ritonavir (ATV/r), or darunavir/ritonavir (DRV/r), when used in combination with tenofovir DF/emtricitabine (TDF/FTC), for treatment-naive adults with HIV-1 infection in the United States (US).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
